首頁 > 市場調查報告書 > 製藥

循環系統

靜脈血栓栓塞症治療市場規模、佔有率和成長分析（按產品、適應症、最終用戶和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1897181

靜脈血栓栓塞症治療市場規模、佔有率和成長分析（按產品、適應症、最終用戶和地區分類）—產業預測（2026-2033 年）

Venous Thromboembolism Treatment Market Size, Share, and Growth Analysis, By Product, By Disease Indication, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球靜脈血栓栓塞症治療市場規模預計在 2024 年達到 23.1 億美元，從 2025 年的 24.3 億美元成長到 2033 年的 35.8 億美元，在預測期（2026-2033 年）內複合年成長率為 5%。

全球靜脈血栓栓塞症(VTE) 治療市場專注於解決血栓這一嚴重的健康問題，血栓可導致肺動脈栓塞和深層靜脈栓塞症等疾病。推動市場發展的關鍵因素包括與久坐生活方式、人口老化和外科手術相關的 VTE 盛行率不斷上升，從而催生了對有效治療方法的需求。抗凝血治療的創新，特別是直介面服抗凝血劑 (DOAC) 和注射劑，與傳統療法相比，在改善患者預後的同時降低了出血風險。人們對 VTE 風險因素的認知不斷提高，以及對早期診斷重要性的重視，也進一步推動了市場擴張。儘管仍存在一些挑戰，例如需要製定個人化的治療策略和確保患者依從性，但該市場在提供拯救生命的治療方面發揮的關鍵作用仍然凸顯。

全球靜脈血栓栓塞症治療市場促進因素

靜脈血栓栓塞症症（VTE）病例的不斷增加是推動全球治療市場發展的主要因素。這一成長歸因於多種因素，包括人口老化、久坐的生活方式以及術後併發症風險的增加。鑑於VTE可能帶來的嚴重健康後果，對有效檢測和治療方案的需求日益迫切。人們對VTE及其潛在併發症的認知不斷提高，預計將增加對創新治療方法和管理方案的需求，從而進一步推動市場擴張和新治療方法的研發。

限制全球靜脈血栓栓塞症治療市場的因素

全球靜脈血栓栓塞症治療市場面臨許多挑戰，主要歸因於靜脈血栓栓塞症治療的複雜性。治療方案可能複雜且耗時，導致患者難以堅持治療。對聯合療法的依從性差會影響治療效果，並最終降低現有治療方案的整體療效。隨著患者努力應對治療方案的種種要求，依從性差的風險也會增加，這成為靜脈血栓栓塞症有效治療進展的一大障礙。應對這些挑戰對於提高該市場的治療成功率至關重要。

全球靜脈血栓栓塞症治療市場趨勢

全球靜脈血栓栓塞症）治療市場呈現出顯著趨勢，即直介面服抗凝血劑（DOAC）正逐漸成為首選治療方案。這項轉變主要得益於DOAC（如Apixaban、Rivaroxaban和艾多沙班）的便捷易用，與Warfarin等傳統抗凝血劑相比，它們所需的監測也更少。此外，DOAC在預防和治療VTE方面均展現出與傳統抗凝血劑相當甚至更優的療效，使其成為醫護人員和患者的理想選擇。這種不斷變化的治療偏好也推動了旨在改善患者預後和簡化VTE治療通訊協定的各項努力。

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- 強生公司（美國）
- 輝瑞公司（美國）
- 拜耳股份公司（德國）
- 百時美施貴寶（美國）
- 第一三共株式會社（日本）
- 勃林格殷格翰（德國）
- 諾華公司（瑞士）
- Aspen Pharmacare Holdings Limited（南非）
- 雅培實驗室（美國）
- 美敦力公司（愛爾蘭）
- 波士頓科學公司（美國）
- 康德樂公司（美國）
- 泰爾茂株式會社（日本）
- 庫克醫療（美國）
- Getinge AB（瑞典）
- 泰利福公司（美國）
- 史密斯+內普（英國）
- 百特國際有限公司（美國）
- 儀器實驗室（美國）

結論與建議

簡介目錄

Product Code: SQMIG35D2196

Global Venous Thromboembolism Treatment Market size was valued at USD 2.31 Billion in 2024 and is poised to grow from USD 2.43 Billion in 2025 to USD 3.58 Billion by 2033, growing at a CAGR of 5% during the forecast period (2026-2033).

The global market for venous thromboembolism (VTE) treatment focuses on addressing the serious health issue of blood clots that can lead to conditions such as pulmonary embolism and deep vein thrombosis. Key drivers of this market include the rising prevalence of VTE linked to sedentary lifestyles, aging populations, and surgical interventions, which creates a demand for effective treatments. Innovations in anticoagulant therapies, particularly direct oral anticoagulants (DOACs) and injectable options, enhance patient outcomes while reducing bleeding risks compared to traditional treatments. Growing awareness of VTE risk factors and the importance of early diagnosis further fuels market expansion. Challenges remain, including the need for personalized treatment strategies and ensuring patient adherence, underscoring the market's critical role in delivering life-saving care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segments Analysis

Global Venous Thromboembolism Treatment Market is segmented by Product, Disease Indication, End User and region. Based on Product, the market is segmented into Non-Segmented Pneumatic Compression Pumps, Segmented Pneumatic Compression Pumps without Gradient, Segmented Pneumatic Compression Pumps with Calibrated Gradient, Upper Pneumatic Compression Sleeves, Lower Pneumatic Compression Sleeves, Permanent Inferior Vena Cava Filters, Retrievable Inferior Vena Cava Filters, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices and Catheter-Directed Thrombolysis (CDT) Devices. Based on Disease Indication, the market is segmented into Deep Venous Thrombosis and Pulmonary Embolism. Based on End User, the market is segmented into Hospitals, Catheterisation Laboratories and Ambulatory Surgical Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Venous Thromboembolism Treatment Market

The rising prevalence of Venous Thromboembolism (VTE) cases is a primary factor propelling the global treatment market. This increase can be attributed to several influences, including an aging population, sedentary lifestyles, and heightened risks associated with post-surgical conditions. Given the serious health implications associated with VTE, the need for effective detection and treatment solutions has become increasingly urgent. As awareness of VTE and its potential complications grows, the demand for innovative therapies and management options is expected to rise, further driving market expansion and the development of new treatment modalities.

Restraints in the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism Treatment market faces significant challenges due to the complexities associated with managing venous thromboembolism. Treatment regimens can be intricate and may extend over an extended duration, leading to difficulties in patient compliance. This lack of adherence to prescribed therapies can adversely affect treatment outcomes, ultimately hindering the overall effectiveness of the therapeutic options available. As patients grapple with the demands of their regimens, the likelihood of non-compliance increases, posing a crucial barrier that can deter progress in managing venous thromboembolism effectively. Addressing these issues is essential for improving treatment success rates in this market.

Market Trends of the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market is witnessing a significant trend towards the adoption of Direct Oral Anticoagulants (DOACs) as the preferred choice for therapy. This shift is driven by the convenience and ease of administration associated with DOACs such as apixaban, rivaroxaban, and edoxaban, which require minimal monitoring compared to traditional anticoagulants like warfarin. Furthermore, DOACs have demonstrated comparable or superior efficacy in both the prevention and treatment of VTE, making them an attractive option for healthcare providers and patients alike. This evolving preference underscores a broader commitment to enhancing patient outcomes and streamlining treatment protocols in VTE management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Venous Thromboembolism Treatment Market Size by Product & CAGR (2026-2033)

Market Overview
Non-Segmented Pneumatic Compression Pumps
Segmented Pneumatic Compression Pumps without Gradient
Segmented Pneumatic Compression Pumps with Calibrated Gradient
Upper Pneumatic Compression Sleeves
Lower Pneumatic Compression Sleeves
Permanent Inferior Vena Cava Filters
Retrievable Inferior Vena Cava Filters
Embolectomy Balloon Catheters
Percutaneous Thrombectomy Devices
Catheter-Directed Thrombolysis (CDT) Devices

Global Venous Thromboembolism Treatment Market Size by Disease Indication & CAGR (2026-2033)

Market Overview
Deep Venous Thrombosis
Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Catheterisation Laboratories
Ambulatory Surgical Centres

Global Venous Thromboembolism Treatment Market Size & CAGR (2026-2033)

North America (Product, Disease Indication, End User)
- US
- Canada
Europe (Product, Disease Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Disease Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Disease Indication, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Disease Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Pharmacare Holdings Limited (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cook Medical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Getinge AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teleflex Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith+Nephew (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Instrumentation Laboratory (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments